Article
Therapy of chronic hepatitis C: a critical review.
Current drug targets. Infectious disorders - 1 Mar 2003
Saracco G, Olivero A, Ciancio A, Carenzi S, Rizzetto M
Abstract excerpt
Combination therapy (Interferon plus ribavirin) is the current therapeutic gold standard for naive Hepatitis C Virus (HCV)-positive patients and with the recent advent of pegylated (PEG) IFN the rate of the sustained virological response (HCV-RNA clearance 6 months after the end of treatment) is about 54%-56% with a therapeutical gain mainly among patients with unfavourable HCV genotype (1a, 1b); in this subset...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
